Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down – Here’s Why

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares gapped down prior to trading on Thursday. The stock had previously closed at $14.81, but opened at $10.70. Iovance Biotherapeutics shares last traded at $10.0730, with a volume of 17,767,226 shares traded.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients in the IOV-LUN-202 trial, consistent with earlier results. The KRAS wild-type subgroup posted a 43.3% response rate, versus 11.4% for KRAS-mutant disease, while a biomarker-enriched subgroup reached 59.1%. The data support a planned supplemental Biologics License Application for lifileucel in non-squamous mNSCLC in 2027. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: Iovance plans to begin enrollment in November 2026 for POSITILITY, a biomarker-enriched study with registrational intent, expanding its precision TIL strategy in lung cancer. Iovance Precision TIL Strategy
• Positive Sentiment: Unusually high options activity showed traders purchased 28,173 call contracts, approximately 70% above typical daily call volume, indicating increased speculative bullish interest.
• Positive Sentiment: Zacks upgraded IOVA from “hold” to “strong-buy,” and its earnings preview identifies factors that could support a beat in the upcoming report. Iovance Earnings Estimates Preview
• Neutral Sentiment: Additional lifileucel results showed a 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma, broadening the potential opportunity for the company’s TIL platform. Lifileucel Sarcoma Results
• Negative Sentiment: Some coverage argues that IOVA may already be fully valued following recent melanoma and ESMO-related data, raising the risk of a “sell-the-news” reaction even as the clinical results remain promising. Iovance Valuation Analysis

Analysts Set New Price Targets

Several research analysts recently weighed in on IOVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, September 29th. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Barclays upped their price target on shares of Iovance Biotherapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Tuesday, October 13th. HC Wainwright upped their price target on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Finally, UBS Group raised their price objective on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.20.

Iovance Biotherapeutics Trading Down 35.2%

The company’s 50-day moving average is $11.35 and its 200 day moving average is $5.76. The firm has a market cap of $4.34 billion, a PE ratio of -13.04 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $99.31 million during the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The company’s revenue for the quarter was up 65.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.33) earnings per share. On average, research analysts predict that Iovance Biotherapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Iovance Biotherapeutics in the third quarter worth $343,000. MGO One Seven LLC increased its position in Iovance Biotherapeutics by 22.1% during the third quarter. MGO One Seven LLC now owns 15,747 shares of the biotechnology company’s stock worth $233,000 after buying an additional 2,854 shares during the last quarter. State of Wyoming bought a new position in Iovance Biotherapeutics during the third quarter valued at about $246,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Iovance Biotherapeutics by 21.7% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 131,450 shares of the biotechnology company’s stock valued at $1,948,000 after buying an additional 23,400 shares in the last quarter. Finally, Partners Wealth Management LLC acquired a new stake in shares of Iovance Biotherapeutics in the third quarter worth about $148,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.